A model for interrogating the clinico-radiological paradox in multiple sclerosis: internuclear ophthalmoplegia
Multiple Sclerosis
Ophthalmoplegia
Eye Movements
Magnetic Resonance Imaging
3. Good health
Radiography
03 medical and health sciences
Cross-Sectional Studies
Ocular Motility Disorders
0302 clinical medicine
Saccades
Humans
DOI:
10.1111/ene.14723
Publication Date:
2021-01-15T04:29:45Z
AUTHORS (9)
ABSTRACT
AbstractBackground and purposeThe clinico‐radiological paradox in multiple sclerosis (MS) is well recognized, relevant and yet poorly understood. The suitability of an in vivo model for the clinico‐radiological paradox was tested, using internuclear ophthalmoplegia (INO) and the medial longitudinal fasciculus (MLF).MethodsIn this cross‐sectional study lesions of the MLF were rated by an experienced MS neuroradiologist blinded to all other information. The presence of an INO was objectively determined by a validated infrared oculography protocol (DEMoNS). Clinical information, including the National Eye Institute Visual Function Questionnaire, was obtained.ResultsThis study included 202 patients with MS. The clinico‐radiological paradox occurred in 50 patients (25%). This consisted of 45 patients having an INO without an MLF lesion and five patients with an MLF lesion but without an INO. The visual function overall score was related to the presence of an INO (p = 0.016), but not to MLF lesions seen on magnetic resonance imaging (MRI) (p = 0.207). A consensus list of potential causes for the clinico‐radiological paradox was compiled and the MRI images were deposited in a repository.ConclusionThis study provides an objective and quantitative model to investigate the clinico‐radiological paradox. Our data suggest that pathology of the MLF is more frequently detected and more clinically relevant by infrared oculography than by MLF lesion rating on MRI.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES ()
CITATIONS (9)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....